Related Experiment Video

Updated: Feb 10, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

[Specific Features of Pharmacotherapy of Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection

V N Larina1, M V Leonova1, I I Chukaeva1

  • 1Federal State Budgetary Educational Institution of Higher Education, "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation.

Kardiologiia
|May 22, 2018
PubMed

Insights

This review summarizes current pharmacotherapy for chronic heart failure with preserved ejection fraction, focusing on guideline-recommended drugs and novel strategies targeting myocardial fibrosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure with preserved ejection fraction (HFpEF) affects a significant patient population.
  • Current treatment guidelines for HFpEF are evolving.
  • Understanding therapeutic options is crucial for managing HFpEF.

Purpose of the Study:

  • To review the pharmacotherapy of chronic heart failure with preserved left ventricular ejection fraction (HFpEF).
  • To discuss current clinical guidelines for HFpEF management.
  • To explore new therapeutic approaches for HFpEF, including those targeting myocardial fibrosis.

Main Methods:

  • Review of meta-analyses of randomized clinical trials.
  • Analysis of observational studies.
  • Examination of current clinical guidelines.

Main Results:

  • Discussion of renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists in HFpEF.
  • Evaluation of established pharmacotherapies based on meta-analyses and observational data.
  • Consideration of emerging therapies impacting myocardial fibrosis.

Conclusions:

  • Pharmacotherapy for HFpEF involves established drug classes guided by current recommendations.
  • Novel therapeutic strategies focusing on myocardial fibrosis represent a promising future direction for HFpEF treatment.
  • Further research into fibrosis-modulating agents is warranted for improved HFpEF outcomes.

Keywords:
angiotensin converting enzyme inhibitorsbetablockersheart failuremineralocorticoid receptor antagonistspharmacotherapypreserved left ventricular ejection fraction

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
391
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
356